Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00007540 |
Prostate cancer is diagnosed in approximately 334,500 men each year and accounts for nearly 41,800 deaths in the United States. Prostate cancer is the leading cancer affecting veterans and the second leading cancer among all Americans. The causes of prostate cancer and, particularly, the reasons for the unusually high incidence rates in African-Americans remain obscure. Dietary factors likely play a role in fatal cases, while hormones are also important in regulating prostate cancer growth. Dr. Charles Huggins recognized this effect in the 1940?s, with androgen deprivation remaining as the cornerstone of therapy for advanced disease. Despite the strong circumstantial evidence, neither epidemiologic studies nor basic sciences have produced clear insight into the etiologic role of hormones. However, recent observations regarding androgen receptor gene polymorphisms and their relation to endocrine expression and prostate cancer risk may be providing important clues as to how an etiologic role might be mediated at the molecular level. Thus, it is important to attempt to identify genetic markers of high-risk cancer patients for necessary screening and counseling efforts.
Condition |
---|
Prostate Cancer Prostatic Neoplasms |
Study Type: | Observational |
Study Design: | Natural History |
Official Title: | Study of Prostate Cancer in Black and White U.S. Veterans |
Study Start Date: | April 1998 |
Estimated Study Completion Date: | September 2000 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Veterans who undergo prostate biopsy where biopsy results are positive or PSA less than 10Ng/ml.
Study ID Numbers: | 709D |
Study First Received: | December 29, 2000 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00007540 |
Health Authority: | United States: Federal Government |
Prostate cancer CAG repeat sequence |
Prostatic Diseases Genital Neoplasms, Male Hydroquinone |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Radiation-Protective Agents Neoplasms Antioxidants Neoplasms by Site |
Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Protective Agents Pharmacologic Actions |